Gastric inhibitory polypeptide does not inhibit gastric emptying in humans (Q44215026)

30 November 2017

Gastric inhibitory polypeptide does not inhibit gastric emptying in humans (English)

1 reference

30 November 2017

5

1 reference

30 November 2017

Juris J Meier

1

1 reference

30 November 2017

Oliver Goetze

2

1 reference

30 November 2017

Jens Anstipp

3

1 reference

30 November 2017

Dirk Hagemann

4

1 reference

30 November 2017

Wolfgang E Schmidt

6

1 reference

30 November 2017

Baptist Gallwitz

7

1 reference

30 November 2017

Michael A Nauck

8

1 reference

30 November 2017

16 December 2003

1 reference

American Journal of Physiology - Endocrinology and Metabolism

30 November 2017

1 reference

30 November 2017

286

1 reference

30 November 2017

4

1 reference

30 November 2017

E621-5

1 reference

A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence

30 November 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Gastric emptying in diabetes: clinical significance and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Immunoreactive gastric inhibitory polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Gastric emptying and release of incretin hormones after glucose ingestion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Role of GIP and insulin in glucose-induced changes in intestinal motility patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00499.2003

10.1152/AJPENDO.00499.2003

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference